中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

80 records (took 0.029 seconds)

    Matriptase, a serine protease and its applications
    51.
    发明授权
    Matriptase, a serine protease and its applications 有权
    Matriptase，丝氨酸蛋白酶及其应用

    公开(公告)号：US07355015B1

    公开(公告)日：2008-04-08

    申请号：US09936333

    申请日：2000-03-10

    Applicant: Robert B. Dickson ,  Chen-Yong Lin ,  Michael Johnson ,  Shaomeng Wang ,  Istvan Enyedy

    Inventor： Robert B. Dickson ,  Chen-Yong Lin ,  Michael Johnson ,  Shaomeng Wang ,  Istvan Enyedy

    IPC: C07K16/00 ,  C07K16/40 ,  A61K38/43

    CPC classification number: A61K49/0039 ,  A61K38/00 ,  A61K49/0056 ,  A61K49/0058 ,  A61K51/10 ,  C12Q1/37 ,  G01N33/573 ,  G01N2333/96433 ,  G01N2500/20

    Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.

    Abstract translation: 本发明涉及通过检测组织中单链或双链形式的matriptase的存在来检测乳腺或其他组织或病理状况中的恶性肿瘤或恶性前病变的方法。 本发明进一步涉及通过施用抑制有效量的Bowman-Birk抑制剂（BBIC）浓缩物或其它片剂酶抑制剂的肿瘤形成来治疗恶性肿瘤的方法，所述恶性肿瘤具有基质酶产生的表型。 本发明还涉及编码matriptase蛋白质或其片段的核酸，以及其用于结构阐明和建模以鉴定其它抑制剂的用途，以及鉴定片段酶调节剂（包括活化剂和抑制剂）的方法。

    Gossypol co-crytals and the use thereof
    52.
    发明申请
    Gossypol co-crytals and the use thereof 有权
    棉酚共同合作伙伴及其用途

    公开(公告)号：US20070293585A1

    公开(公告)日：2007-12-20

    申请号：US11818766

    申请日：2007-06-15

    Applicant: Shaomeng Wang ,  Jiangyong Chen

    Inventor： Shaomeng Wang ,  Jiangyong Chen

    IPC: A61K31/11 ,  A61P31/00 ,  A61P31/04 ,  A61P33/00 ,  A61P35/00

    CPC classification number: A61K31/11

    Abstract: This invention relates to compositions comprising co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

    Abstract translation: 本发明涉及包含（ - ） - 棉酚与C 1-8 - 羧酸或C 1-8 - 磺酸的共晶体的组合物，其可用作 Bcl-2家族蛋白。 本发明还涉及（ - ） - 棉酚与C 1-8 - 羧酸或C 1-8 - 磺酸的共晶体用于诱导细胞凋亡 细胞和致敏细胞诱导凋亡细胞死亡。

    Gossypol co-crystals and the use thereof
    55.
    发明申请
    Gossypol co-crystals and the use thereof 有权
    棉酚共晶及其用途

    公开(公告)号：US20050234135A1

    公开(公告)日：2005-10-20

    申请号：US11089096

    申请日：2005-03-24

    Applicant: Shaomeng Wang ,  Jiangyong Chen

    Inventor： Shaomeng Wang ,  Jiangyong Chen

    IPC: A61K31/11

    CPC classification number: A61K31/11

    Abstract: This invention relates to compositions comprising co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

    Abstract translation: 本发明涉及包含（ - ） - 棉酚与C 1-8 - 羧酸或C 1-8 - 磺酸的共晶体的组合物，其可用作 Bcl-2家族蛋白。 本发明还涉及（ - ） - 棉酚与C 1-8 - 羧酸或C 1-8 - 磺酸的共晶体用于诱导细胞凋亡 细胞和致敏细胞诱导凋亡细胞死亡。

    Small molecule inhibitors targeted at Bcl-2
    56.
    发明授权
    Small molecule inhibitors targeted at Bcl-2 有权
    针对Bcl-2的小分子抑制剂

    公开(公告)号：US06703382B2

    公开(公告)日：2004-03-09

    申请号：US09930237

    申请日：2001-08-16

    Applicant: Shaomeng Wang ,  Dajun Yang ,  Istvan J. Enyedy

    Inventor： Shaomeng Wang ,  Dajun Yang ,  Istvan J. Enyedy

    IPC: A61K31655

    CPC classification number: A61K31/655 ,  A61K31/675 ,  A61K31/70 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    Abstract: A method for promotion of cell death in tumor cells using tricylo-dibenzo-diazocine-dioxides that bind to a pocket of Bcl-2 and block the Bcl-2 anti-apoptotic function. A method of use of a compound of the general structural Formula (I) for use in treatment of cancer: wherein X and Y, and R and R1, and R2, R3, R4 and R5, and A and A1, have any of the values defined in the specification.

    Abstract translation: 使用结合Bcl-2的口袋并阻断Bcl-2抗凋亡功能的三羟甲基 - 二苯并二氮杂环己烷二氧化物促进肿瘤细胞中细胞死亡的方法。 使用通式（I）化合物用于治疗癌症的方法：其中X和Y，以及R和R 1，R 2，R 3，R 4和R 5以及A和A 1具有 规范中定义的值。

    Substituted 2-pyrrolidinone activators of PKC
    57.
    发明授权
    Substituted 2-pyrrolidinone activators of PKC 有权
    PKC的取代的2-吡咯烷酮激活剂

    公开(公告)号：US06284784B1

    公开(公告)日：2001-09-04

    申请号：US09339072

    申请日：1999-06-23

    Applicant: Alan P. Kozikowski ,  Shaomeng Wang ,  Lixin Qiao

    Inventor： Alan P. Kozikowski ,  Shaomeng Wang ,  Lixin Qiao

    IPC: A61K3140

    CPC classification number: C07D207/26

    Abstract: Compounds of formula I: wherein R1 and R2 have any of the values defined in the specification, and their pharmaceutically acceptable salts, are PKC activators and are useful for treating diseases, such as, for example, cancer. Also disclosed are pharmaceutical compositions comprising compounds of formula I, processes for preparing compounds of formula I, and intermediates useful for preparing compounds of formula I.

    Abstract translation: 式I化合物：其中R 1和R 2具有说明书中定义的任何值及其药学上可接受的盐，是PKC激活剂，并且可用于治疗疾病，例如癌症。 还公开了包含式I化合物，式I化合物的方法和可用于制备式I化合物的中间体的药物组合物。

    Heregulin antagonists and methods for their use
    58.
    发明授权
    Heregulin antagonists and methods for their use 失效
    促胰岛素拮抗剂及其使用方法

    公开(公告)号：US6143740A

    公开(公告)日：2000-11-07

    申请号：US308396

    申请日：1999-08-16

    Applicant: Dajun Yang ,  Shaomeng Wang ,  Alan P. Kozikowski ,  Marc E. Lippman

    Inventor： Dajun Yang ,  Shaomeng Wang ,  Alan P. Kozikowski ,  Marc E. Lippman

    IPC: C07D498/18 ,  A61K31/34 ,  A61K31/395 ,  A61K31/495 ,  A61K31/496 ,  A61K31/551 ,  A61K31/655 ,  A61P35/00 ,  A61P43/00 ,  C07D498/08 ,  A61K31/33 ,  C07K1/00 ,  C07K16/00

    CPC classification number: A61K31/708 ,  A61K31/395 ,  A61K31/495 ,  A61K31/496 ,  A61K31/551 ,  A61K31/655 ,  A61K31/704 ,  A61K31/7076 ,  C07D498/08

    Abstract: The invention provides a method of inhibiting cancer cell growth, and thereby of treating cancer comprising administering to a mammal afflicted with cancer an effective amount of the compound of formula (I), wherein the variables of R.sub.1, and R.sub.2 have the meanings defined in the specification. The present invention also provides novel compounds of formula (I) as well as novel pharmaceutical compositions and intermediates useful for preparing compounds of formula (I). The figure illustrates the structure and binding activity of compounds of the invention and some of the rifamycin analogs.______________________________________ ##STR1## ______________________________________ Compounds R.sub.1 = ______________________________________ A1 --OH A2 --OH A3 --OH A4 --OH A5 --OH A6 --OH A7 --OH - A8 ##STR2## ______________________________________ Compounds R.sub.2 = ______________________________________ A1 #STR3## - A2 #STR4## - A3 #STR5## - A4 #STR6## - A5 #STR7## - A6 #STR8## - A7 #STR9## - A8 --H ______________________________________ Compounds IC.sub.50 (1) IC.sub.50 (2) ______________________________________ A1 10 uM 1 uM A2 10 uM 3 uM A3 10 uM 3 uM A4 50 uM 5 uM A5 >500 uM >50 uM A6 >500 uM >50 uM A7 >200 uM >50 uM A8 >500 M >50 uM ______________________________________

    Abstract translation: PCT No.PCT / US97 / 21474 Sec。 371日期1999年8月16日 102（e）1999年8月16日PCT 1997年11月19日PCT公布。 第WO98 / 21956号公报 日期1998年5月28日本发明提供抑制癌细胞生长，从而治疗癌症的方法，包括向患有癌症的哺乳动物施用有效量的式（I）化合物，其中R1和R2的变量具有 在本说明书中定义的含义。 本发明还提供新的式（I）化合物以及可用于制备式（I）化合物的新型药物组合物和中间体。 该图示出了本发明化合物和一些利福霉素类似物的结构和结合活性。 - 化合物R1 = -Al-OH-A2-OH-A3-OH-A4-OH-A5-OH-A6-OH-A7 -OH - - A8化合物R2 = 图像 - - A2 - - A3 - - A4 GE> - - A7 - - A8 -H - 化合物IC50（1）IC50（2） - A1 10 uM 1 uM - A2 10 uM 3 uM - A3 10 uM 3 uM - A4 50 uM 5 uM - A5> 500 uM> 50 uM - A6> 500 uM> 50 uM - A7> 200 uM> 50 uM - A8> 500 M> 50 uM -

    Bivalent diazo bicyclic Smac mimetics and the uses thereof
    60.
    发明授权
    Bivalent diazo bicyclic Smac mimetics and the uses thereof 有权
    二价重氮二环Smac模拟物及其用途

    公开(公告)号：US08815927B2

    公开(公告)日：2014-08-26

    申请号：US13503366

    申请日：2010-10-20

    Applicant: Shaomeng Wang ,  Haiying Sun

    Inventor： Shaomeng Wang ,  Haiying Sun

    IPC: C07D487/04 ,  C07D403/14 ,  C07D245/04 ,  C07D519/00

    CPC classification number: C07D519/00 ,  C07D487/04

    Abstract: The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The invention also relates to the use of bivalent diazo bicyclic Smac mimetics for inducing or sensitizing cells to the induction of apoptotic cell death. Thus, compounds of the invention are useful in the treatment, amelioration, or prevention of hyperproliferative diseases such as cancer.

    Abstract translation: 本发明涉及通过共价接头连接以产生二价物质的重氮二环Smac模拟物。 二价重氮双环Smac模拟物作为细胞凋亡蛋白抑制剂（IAP）的抑制剂起作用。 本发明还涉及二价重氮二环Smac模拟物用于诱导或致敏细胞诱导凋亡细胞死亡的用途。 因此，本发明的化合物可用于治疗，改善或预防过度增殖性疾病如癌症。

Patent Agency Ranking